Print

TetraLogic Pharmaceuticals Licenses Exclusive Rights to Novel Necrosis Inhibitors From Harvard Medical School  
3/9/2009 10:36:27 AM

MALVERN, PA--(Marketwire - March 9, 2009) - TetraLogic Pharmaceuticals, a privately held biopharmaceutical company, announced today that the Company executed a license agreement under which it acquired exclusive worldwide rights from Harvard University to commercialize novel necrostatin compounds and related drug discovery technology developed at Harvard Medical School. Necrostatins are small molecule compounds that block a programmed cell death process called necroptosis that would otherwise kill cells by necrosis. Necroptosis and the potential effect of necrostatins were originally discovered by Professor Dr. Junying Yuan, a pioneer and a recognized leader in the field, and Dr. Alexei Degterev, at the time a member of Dr. Yuan's lab at the Department of Cell Biology, Harvard Medical School. Further improvement of necrostatin compounds was achieved in collaboration with Dr. Greg Cuny of the Harvard NeuroDiscovery Center Laboratory for Drug Discovery in Neurodegeneration.

Necrotic cell death occurs in the course of debilitating acute and chronic conditions including neurological injuries, neurodegenerative diseases, cardiovascular injuries, liver and kidney diseases and injuries, burns, transplant rejections and ocular diseases and injuries. Necrostatins have shown potent activity in a variety of preclinical models representing their possible clinical indications. TetraLogic intends to commence human clinical studies of necrostatins during mid-2010.

John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals, stated, "Necrostatins have the potential to treat debilitating diseases and conditions where current therapies are inadequate or non-existent. We are excited about translating this pioneering avenue of research into important new drugs." The necrostatin program fits with capabilities of TetraLogic and its Inhibitor of Apoptosis Proteins Antagonist program where the Company expects to commence human clinical studies with a novel drug to treat cancer during 2009.

"This agreement with TetraLogic marks an important step forward for the development of necrostatins," said Dr. Yuan. "Successful application of necrostatins for human disease may prove transformative by providing new therapeutic modalities for diseases that have no existing treatment."

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing drugs that modulate cell death pathways. To date, TetraLogic has raised a total of $44 million through private financings. The Company's investors include Amgen Ventures, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company's website at www.tetralogicpharma.com.


//-->